A Study to Evaluate ALN-6222 in Participants With Obesity
Recruiting · NCT07624071 · Interventional (participants receive a specific treatment) · Lead sponsor: Alnylam Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
ALN-6222Placebo
What this trial is about
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2
- Has a hemoglobin A1c \<6.5%
Exclusion criteria
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (ULN)
- Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
- Has an estimated glomerular filtration (eGFR) of \<60 mL/min/1.73m\^2 at screening
- Note: other protocol defined inclusion / exclusion criteria apply
Where it is running
1 location listed.
- Clinical Trial Site - Mount Royal, Canada